{"denoms":[{"counts":[{"groupId":"BG000","value":"126"},{"groupId":"BG001","value":"61"},{"groupId":"BG002","value":"187"}],"units":"Participants"}],"groups":[{"description":"Participants received AG-120 500 mg, tablet, orally, QD in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up, or the sponsor ended the study for up to approximately 45 months.","id":"BG000","title":"AG-120"},{"description":"Participants received AG-120 matched placebo, orally, QD in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up or the sponsor ended the study for up to approximately 7 months. Participants who experienced disease progression and received placebo were allowed to cross over and receive AG-120.","id":"BG001","title":"Placebo"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.97","value":"60.3"},{"groupId":"BG001","spread":"10.38","value":"62.9"},{"groupId":"BG002","spread":"10.82","value":"61.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"82"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"119"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"68"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"9"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"84"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"124"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}],"title":"Not Reported"},{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"52"}],"title":"Missing"}],"title":"Ethnicity"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"23"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"71"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"106"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Other"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Not Reported"},{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"52"}],"title":"Missing"}],"title":"Race"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"Intent-To-Treat (ITT) Set included all participants who were randomized, with the treatment group designated according to the randomization."}